# Sunshine Biopharma Inc. (SBFM)

Source: https://www.quantisnow.com/company/SBFM
Generated: 2026-11-17T09:55:16.452Z

- Ticker: SBFM
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001402328
- Website: https://www.sunshinebiopharma.com

## About

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.

## Latest SBFM news and filings

- 2026-11-13 21:12 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-sunshine-biopharma-inc-6790651)
- 2026-11-12 21:31 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-sunshine-biopharma-inc-6788440)
- 2026-11-12 21:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-sunshine-biopharma-inc-6787782)
- 2026-11-10 22:49 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-sunshine-biopharma-inc-6784816)
- 2026-10-27 16:15 UTC [SEC Form DEF 14C filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14c-filed-by-sunshine-biopharma-inc-6758977)
- 2026-10-22 13:00 UTC [Market Insight] [Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing](https://www.quantisnow.com/insight/sunshine-biopharma-announces-reverse-stock-split-to-maintain-nasdaq-listing-6754629)
- 2026-10-14 21:21 UTC [SEC Form PRE 14C filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-pre-14c-filed-by-sunshine-biopharma-inc-6746915)
- 2026-10-14 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-sunshine-biopharma-inc-6746541)
- 2026-10-09 21:25 UTC [SEC Form 8-K] [SEC Form 8-K filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-sunshine-biopharma-inc-6743262)
- 2026-10-09 21:24 UTC [SEC Form 424B4 filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-424b4-filed-by-sunshine-biopharma-inc-6743254)
- 2026-10-09 15:17 UTC [Market Insight] [Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering](https://www.quantisnow.com/insight/sunshine-biopharma-announces-closing-of-up-to-204-million-public-6742632)
- 2026-10-08 12:00 UTC [Market Insight] [Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering](https://www.quantisnow.com/insight/sunshine-biopharma-inc-announces-pricing-of-60-million-public-offering-6741101)
- 2026-10-08 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-sunshine-biopharma-inc-6740891)
- 2026-10-02 20:49 UTC [SEC Form S-1] [SEC Form S-1 filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-sunshine-biopharma-inc-6735022)
- 2026-09-28 10:00 UTC [SEC Form DEF 14C filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14c-filed-by-sunshine-biopharma-inc-6726966)
- 2026-09-24 13:00 UTC [Market Insight] [Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio](https://www.quantisnow.com/insight/sunshine-biopharma-launches-generic-zofranr-in-canada-expanding-oncology-supportive-6725034)
- 2026-09-16 20:10 UTC [SEC Form PRE 14C filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-pre-14c-filed-by-sunshine-biopharma-inc-6717528)
- 2026-09-16 20:05 UTC [SEC Form 8-K] [Sunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/sunshine-biopharma-inc-filed-sec-form-8-k-submission-of-matters-6717482)
- 2026-09-16 13:00 UTC [Market Insight] [Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies](https://www.quantisnow.com/insight/sunshine-biopharma-advances-lead-coronavirus-drug-candidate-into-ind-enabling-studies-6717077)
- 2026-09-11 21:00 UTC [SEC Form 8-K] [Sunshine Biopharma Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/sunshine-biopharma-inc-filed-sec-form-8-k-other-events-6713243)
- 2026-09-09 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-sunshine-biopharma-inc-6709038)
- 2026-09-08 21:22 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-sunshine-biopharma-inc-6708732)
- 2026-08-31 13:00 UTC [Market Insight] [Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions](https://www.quantisnow.com/insight/health-canada-approves-sunshine-biopharmas-atenolol-for-treating-and-managing-6699291)
- 2026-08-28 20:15 UTC [SEC Form S-1] [SEC Form S-1 filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-sunshine-biopharma-inc-6698434)
- 2026-08-28 20:05 UTC [SEC Form 8-K] [Sunshine Biopharma Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/sunshine-biopharma-inc-filed-sec-form-8-k-leadership-update-6698329)
- 2026-08-26 13:20 UTC [A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity](https://www.quantisnow.com/insight/a-multibillion-dollar-mrna-cancer-market-is-taking-shape-targeting-lung-6695204)
- 2026-08-26 13:00 UTC [Market Insight] [Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer](https://www.quantisnow.com/insight/sunshine-biopharma-reports-in-vivo-tumor-suppression-with-k11-mrna-6695142)
- 2026-08-19 13:00 UTC [Market Insight] [Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market](https://www.quantisnow.com/insight/sunshine-biopharma-receives-canadian-regulatory-approval-for-enalapril-expanding-into-6687966)
- 2026-08-13 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-sunshine-biopharma-inc-6680378)
- 2026-08-11 20:23 UTC [SEC Form 4] [Director Natan David was granted 58,300 shares, increasing direct ownership by 583% to 68,300 units (SEC Form 4)](https://www.quantisnow.com/insight/director-natan-david-was-granted-58300-shares-increasing-direct-ownership-6676037)
- 2026-08-07 13:00 UTC [Market Insight] [Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market](https://www.quantisnow.com/insight/sunshine-biopharma-launches-amoxicillin-in-canada-and-begins-pharmacy-shipments-6670848)
- 2026-08-04 13:00 UTC [Market Insight] [Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval](https://www.quantisnow.com/insight/sunshine-biopharma-enters-the-28-billion-global-dienogest-market-with-6661374)
- 2026-08-03 12:52 UTC [SEC Form 8-K] [Sunshine Biopharma Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/sunshine-biopharma-inc-filed-sec-form-8-k-other-events-6658962)
- 2026-07-28 12:00 UTC [Market Insight] [Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting](https://www.quantisnow.com/insight/health-canada-approves-sunshine-biopharmas-ondansetron-for-treatment-of-chemotherapy-induced-6650655)
- 2026-07-20 20:34 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-sunshine-biopharma-inc-6642619)
- 2026-07-20 20:27 UTC [SEC Form 8-K] [Sunshine Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/sunshine-biopharma-inc-filed-sec-form-8-k-entry-into-a-6642567)
- 2026-07-20 12:30 UTC [Market Insight] [Sunshine Biopharma and University of Arizona Publish Significant New Research Findings](https://www.quantisnow.com/insight/sunshine-biopharma-and-university-of-arizona-publish-significant-new-research-6642016)
- 2026-07-10 20:54 UTC [SEC Form 8-K] [Sunshine Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/sunshine-biopharma-inc-filed-sec-form-8-k-entry-into-a-6634335)
- 2026-06-25 12:00 UTC [Market Insight] [Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)](https://www.quantisnow.com/insight/sunshine-biopharma-receives-canadian-regulatory-approval-for-generic-arimidexr-6615133)
- 2026-06-08 20:05 UTC [SEC Form DEF 14C filed by Sunshine Biopharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14c-filed-by-sunshine-biopharma-inc-6593270)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SBFM
- Earnings history: https://www.quantisnow.com/earnings/SBFM
- Dividend history: https://www.quantisnow.com/dividends/SBFM
- Insider transactions: https://www.quantisnow.com/insiders/SBFM
- Options chain: https://www.quantisnow.com/options/SBFM
- SEC 8-K filings only: https://www.quantisnow.com/company/SBFM/8-k
- RSS and alerts for SBFM: https://www.quantisnow.com/docs/rss-feeds.md
